Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital dips below year-ago levels
Q1 FY2026 change in working capital of $6.98M (cash outflow) fell 73.0% year over year, behind the +115.1% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -24.4% a year.
Context
- Change in working capital amounted to 18.9% of revenue in FY2025, down 37.5 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -73.0% toward the trailing-twelve-month pace of +115.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (4.8M) USD
- Year-over-year change
- +96.0%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.8M) | +96.0% |
| FY2024 | 2024-12-31 | (118.85M) | -187.2% |
| FY2023 | 2023-12-31 | 136.32M | +1326.8% |
| FY2022 | 2022-12-31 | (11.11M) | -224.8% |
| FY2021 | 2021-12-31 | (3.42M) | — |
Change in Working Capital vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 change in working capital of $14.08M is the 4th largest of the 11 companies compared; the peer median is $1.59M.
- Its year-over-year change of +115.1% is the 4th highest of 11, against a peer median of -48.4%.
- Change in working capital amounts to 245.3% of revenue for TRDA, versus a peer median of 46.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.75M | -37.9% | — | 73.3% | |
| LTM Mar 2026 | $15.79M | +1014.2% | — | — | |
| LTM Mar 2026 | $15.14M | +208.6% | — | 750.8% | |
| LTM Mar 2026 | $14.08M | +115.1% | -24.4% | 245.3% | |
| LTM Mar 2026 | $13.89M | +159.9% | — | — | |
| LTM Mar 2026 | $8.51M | -85.7% | +46.2% | 18.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $3.42M | -181.2% | — | — |
| LTM Mar 2026 | $2.34M | +115.1% | +11.0% | 1.1% | |
| LTM Mar 2026 | $1.66M | -293.7% | +30.6% | — | |
| LTM Mar 2026 | $1.52M | -58.9% | -24.9% | — | |
| LTM Mar 2026 | $531K | -62.5% | — | — | |
| Peer median (excluding TRDA) | $1.59M | -48.4% | +20.8% | 46.0% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.